ArticleAmerican journal of respiratory and critical care medicine2008
Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis.
Article in American journal of respiratory and critical care medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 101 citations in OpenAlex.
- Identifying the potential anti-lung cancer targets of Baicalein using a network pharmacology approach.Scientific reports · 2026Article
- Noncoding RNAs in chronic obstructive pulmonary disease: From pathogenesis to therapeutic targets.Non-coding RNA research · 2024Review
- Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases.Acta pharmaceutica Sinica. B · 2023Review
- SAMD9 Promotes Postoperative Recurrence of Esophageal Squamous Cell Carcinoma by Stimulating MYH9-Mediated GSK3β/β-Catenin Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review.Cell biology international · 2022Review
- Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application.Pharmaceutics · 2022Review
- The miR-23a/27a/24-2 cluster promotes postoperative progression of early-stage non-small cell lung cancer.Molecular therapy oncolytics · 2022Article
- PD-L1Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Inhibition of APE1 Expression Enhances the Antitumor Activity of Olaparib in Triple-Negative Breast Cancer.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Insights on prospects of nano-siRNA based approaches in treatment of Cancer.Frontiers in pharmacology · 2022Review
- CRISPR/CasRx Proof-of-Concept for RNA Degradation: A Future Tool against RNA Viruses?Pharmaceuticals (Basel, Switzerland) · 2021Article
- Adverse immunological responses against non-viral nanoparticle (NP) delivery systems in the lung.Journal of immunotoxicology · 2021Review
- GRP75-mediated upregulation of HMGA1 stimulates stage I lung adenocarcinoma progression by activating JNK/c-JUN signaling.Thoracic cancer · 2021Article
- Nucleic Acid-Based Technologies Targeting Coronaviruses.Trends in biochemical sciences · 2021Review
- Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects.Nanomaterials (Basel, Switzerland) · 2020Review
- A novel miR-7156-3p-HOXD13 axis modulates glioma progression by regulating tumor cell stemness.International journal of biological sciences · 2020Article
- miR-134-5p Promotes Stage I Lung Adenocarcinoma Metastasis and Chemoresistance by Targeting DAB2.Molecular therapy. Nucleic acids · 2019Article
- Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases.Chemico-biological interactions · 2019Review
- miR-150-5p Inhibits Non-Small-Cell Lung Cancer Metastasis and Recurrence by Targeting HMGA2 and β-Catenin Signaling.Molecular therapy. Nucleic acids · 2019Article
- Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.Journal of experimental & clinical cancer research : CR · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleThe low efficiency of conventional therapies in achieving long-term survival of patients with lung cancer calls for the development of novel therapeutic options. Recent advances in aerosol-mediated gene delivery have provided the possibility of an alternative for the safe and effective treatment of lung cancer.
objectivesTo demonstrate the feasibility and emphasize the importance of noninvasive aerosol delivery of Akt1 small interfering RNA (siRNA) as an effective and selective option for lung cancer treatment.
methodsNanosized poly(ester amine) polymer was synthesized and used as a gene carrier. An aerosol of poly(ester amine)/Akt1 siRNA complex was delivered into K-ras(LA1) and urethane-induced lung cancer models through a nose-only inhalation system. The effects of Akt1 siRNA on lung cancer progression and Akt-related signals were evaluated. MEASUREMENTS AND MAIN
resultsThe aerosol-delivered Akt1 siRNA suppressed lung tumor progression significantly through inhibiting Akt-related signals and cell cycle.
conclusionsThe use of poly(ester amine) serves as an effective carrier, and aerosol delivery of Akt1 siRNA may be a promising approach for lung cancer treatment and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.